Kaya Ltd

- Kaya Limited has approval for a rights issue of up to INR 300 crores. - The rights issue process is expected to start after completion of the Kaya DMCC sale, pending local authority approval. - The raised funds from the rights issue will be used to strengthen the balance sheet by repaying loans. - Using cash from the rights issue will enable accelerated clinic expansion without additional borrowing. - Management does not currently share forward-looking statements on profitability or margin targets but expects improvement through expansion and financial restructuring. - No specific mention of new debt fundraising was made during the call; focus is on equity fundraising via the rights issue.

- Kaya Limited is currently finalizing the application of funds from the rights issue, with details to be shared in due course (Page 8). - The company invested in 29 new dermatology machines in Q2, covering Anti-Ageing, Acne, Body, Hair Care, and Laser Hair Reduction services to uplift customer experience and outcomes (Page 3). - Clinic Refresh and Brand Refresh programs are ongoing, including relocating 7 clinics since the start of FY '25 and renovating 4 clinics in Q2 (Page 3). - Expansion plans are underway with accelerated clinic openings, though exact numbers for next year are not disclosed yet (Page 6). - The rights issue, approved up to INR 300 crores, is expected to strengthen the balance sheet and fund expansion without additional borrowing (Pages 6-7). - Strategic collaboration with Marico to scale Kaya's product range outside clinics aims to indirectly boost clinic footfall and brand visibility (Page 4).

- Kaya Limited is focusing on accelerating expansion through a combination of organic and inorganic growth, supported by a rights issue to strengthen the balance sheet. - Revenue growth is currently modest, with a 5% growth in the Clinics business and 4% growth in product sales at clinics in Q2 FY'25 versus the previous year. - New customer acquisition is in double digits, although overall customer count has declined due to a drop in existing customers. - Marketing efforts will continue as customer count and footfall remain critical for growth. - The partnership with Marico aims to scale Kaya’s product range beyond clinics to increase brand visibility, indirectly supporting clinic footfall. - Kaya targets accelerated growth post-rights issue without further borrowing. - Clinic refurbishments and launches continue to improve customer experience and support revenue growth. - Overall, they expect growth momentum to pick up as expansion efforts gain pace and customer acquisition initiatives bear fruit.

- Kaya Limited aims for a path to profitability driven by clinic business scaling both organically and inorganically. - Almost all clinics (except 3) are EBITDA positive; clinic business has approx. 26-27% EBITDA margin. - Expansion plans are to be accelerated post rights issue, which will strengthen the balance sheet and reduce borrowing. - Rights issue up to INR 300 crores approved; timing dependent on completion of Kaya DMCC sale. - Marketing and corporate costs are expected to remain steady; focus is on driving customer acquisition and clinic footfall. - New clinics take ~1.5-2 years to achieve operational breakeven; payback period is 3-4 years. - Anticipated revenue growth of around 5% in clinics with improving operational efficiencies. - No specific forward EPS or profit numbers disclosed due to forward-looking statement restrictions. - Growth in associated product categories (Hair Care, Body Care) and increased brand visibility via partnership with Marico expected to support earnings expansion.

The transcript and presentation details provided do not mention any information related to the current or expected order book or pending orders for Kaya Limited. The discussion primarily focuses on financial performance, clinic profitability, expansion plans, rights issue, and operational updates. No specific data on order backlog or pending orders is disclosed in the Q2 FY '25 earnings call or investor presentation materials.